Glenn Schulman
Investor Relations Contact chez IN8BIO, INC.
Profil
Glenn Schulman is currently the VP, Head-Investor Relations & Communications at IN8bio, Inc. He previously worked as the Director-Investor Relations at CuraGen Corp., Investor Relations Contact at Achillion Pharmaceuticals, Inc., Senior VP-Communications & Investor Relations at Aurinia Pharmaceuticals, Inc., VP-Investor Relations & Corporate Communications at X4 Pharmaceuticals, Inc., and Senior Vice President-Investor Relations at ProKidney Corp.
Dr. Schulman holds a graduate degree from Yale University, an undergraduate degree from Philadelphia College of Pharmacy, and a doctorate degree from Ernest Mario School of Pharmacy.
Postes actifs de Glenn Schulman
| Sociétés | Poste | Début |
|---|---|---|
| IN8BIO, INC. | Investor Relations Contact | 01/04/2024 |
Anciens postes connus de Glenn Schulman
| Sociétés | Poste | Fin |
|---|---|---|
| PROKIDNEY CORP. | Investor Relations Contact | - |
| X4 PHARMACEUTICALS, INC. | Investor Relations Contact | - |
| ACHILLION PHARMACEUTICALS, INC. | Public Communications Contact | - |
| AURINIA PHARMACEUTICALS INC. | Investor Relations Contact | 15/07/2022 |
CuraGen Corp.
 CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | Public Communications Contact | - |
Formation de Glenn Schulman
| Yale University | Graduate Degree |
| Philadelphia College of Pharmacy | Undergraduate Degree |
| Ernest Mario School of Pharmacy | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| AURINIA PHARMACEUTICALS INC. | Health Technology |
| IN8BIO, INC. | Health Technology |
| X4 PHARMACEUTICALS, INC. | Health Technology |
| PROKIDNEY CORP. | Health Technology |
| Entreprise privées | 2 |
|---|---|
CuraGen Corp.
CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | Health Technology |
Achillion Pharmaceuticals, Inc.
 Achillion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Achillion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of oral small molecule complement system inhibitors. Its pipeline includes Danicopan and ACH-5228. The company was founded on August 17, 1998 and is headquartered in Blue Bell, PA. | Health Technology |
